Rexahn Pharmaceuticals, a clinical-stage pharmaceutical company commercializing oncology and central nervous system therapeutics, said the European Patent Office has granted it European patent No. 1819698 for its novel anti-cancer quinoxalinyl-piperazine compounds.  

This European patent covers several new quinoxalinyl-piperazine compounds, the process for their preparation, pharmaceutical composition and a method for their producing an anti-proliferative effect. The patent also covers Rexahn’s pre-clinical compound RX-5902, which is being developed by the company. Human trials are expected to start this year. RX-5902 is an orally-available new chemical entity that exhibits potent anti-tumor properties in several tumors, including melanoma.